Showing 1 posts of 1 posts found.
Eli Lilly has announced that its trial of abemaciclib, in combination with fulvestrant, had met its primary endpoint of progression-free …
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
ESTEVE CDMO adds $17.5m to Illinois expansion
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
Brenntag and dsm-firmenich expand biopharma vitamin partnership
CeramTec expands German production capacity for orthopaedic ceramics